E-Mail
The impact of the COVID-19 pandemic on public health is staggering; more than one hundred million cases and two million deaths worldwide. In response, most countries and local governments have taken substantial measures -- such as travel restrictions and physical distancing -- to keep their citizens safe. Both the pandemic and related protective measures pose challenges for ongoing clinical research studies seeking to treat and prevent the world's greatest public health emergencies including COVID-19, but also Alzheimer's disease and other dementia.
In a new paper from the World-Wide FINGERS network in Alzheimer's & Dementia: Translational Research and Clinical Interventions, first author Susanne Röhr, Ph.D., clinical psychologist at the Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Germany, and colleagues provide timely guidance on the design and management of clinical research during COVID-19 -- specifically on the conduct of lifestyle-based risk reduction studies in people at risk for cognitive decline and dementia.